'The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders' by Rivera, S.C. et al.
RESEARCH Open Access
The impact of patient-reported outcome
data from clinical trials: perspectives from
international stakeholders
Samantha Cruz Rivera1, Christel McMullan1, Laura Jones2, Derek Kyte1,3,4, Anita Slade1,2 and Melanie Calvert1,2,3,4,5,6*
Abstract
Background: Patient-reported outcomes (PROs) are increasingly collected in clinical trials as they provide unique
information on the physical, functional and psychological impact of a treatment from the patient’s perspective.
Recent research suggests that PRO trial data have the potential to inform shared decision-making, support
pharmaceutical labelling claims and influence healthcare policy and practice. However, there remains limited
evidence regarding the actual impact associated with PRO trial data and how to maximise PRO impact to benefit
patients and society. Thus, our objective was to qualitatively explore international stakeholders’ perspectives
surrounding: a) the impact of PRO trial data, b) impact measurement metrics, and c) barriers and facilitators to
effectively maximise the impact of PRO trial data upon patients and society.
Methods: Semi-structured interviews with 24 international stakeholders were conducted between May and
October 2018. Data were coded and analysed using reflexive thematic analysis.
Results: International stakeholders emphasised the impact of PRO trial data to benefit patients and society.
Influence on policy-impact, including changes to clinical healthcare practice and guidelines, drug approval and
promotional labelling claims were common types of PRO impact reported by interviewees. Interviewees suggested
impact measurement metrics including: number of pharmaceutical labelling claims and interviews with healthcare
practitioners to determine whether PRO data were incorporated in clinical decision-making. Key facilitators to PRO
impact highlighted by stakeholders included: standardisation of PRO tools; consideration of health utilities when
selecting PRO measures; adequate funding to support PRO research; improved reporting and dissemination of PRO
trial data by key opinion leaders and patients; and development of legal enforcement of the collection of PRO data.
Conclusions: Determining the impact of PRO trial data is essential to better allocate funds, minimise research
waste and to help maximise the impact of these data for patients and society. However, measuring the impact of
PRO trial data through metrics is a challenging task, as current measures do not capture the total impact of PRO
research. Broader international multi-stakeholder engagement and collaboration is needed to standardise PRO
assessment and maximise the impact of PRO trial data to benefit patients and society.
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Background
Patient-reported outcomes (PROs) are any report of the
patients’ perspectives about the impact of disease and
treatment on their health status, for example quality of
life and symptoms, without the interpretation of a clin-
ician, or anyone else [1, 2]. PRO measures can be classi-
fied as disease-specific or generic instruments [3, 4]. The
former are customised to specific health conditions, pop-
ulations or certain functions; such as the Oxford Hip
Score (OHS) [4, 5]. Generic instruments focus on gen-
eral aspects of health-related quality of life, irrespective
of the disease or health condition of the patient; such as
the 36-Item Short Form Survey (SF-36) [5, 6]. The data
from both instruments can be used to demonstrate dif-
ferent types of impact.
Inclusion of PROs in clinical trials can provide unique
patient-centred data, which can be used to help clini-
cians and patients to make more informed treatment de-
cisions, support pharmaceutical labelling claims and
influence healthcare policy [7–10].
However, the lack of scientifically rigorous PRO data
collection, analysis and reporting is a waste of resources
and hinders the maximisation of PRO trial impact [10–
13]. Our recent systematic review suggested that PRO
trial data have the potential to lead to a range of benefits
for patients and society, which can be measured through
impact metrics [14]. In addition, stakeholders often
focus on narrow and distinct forms of impact [14]. For
instance, the PRO data arising from the Cardiac Resyn-
chronisation – Heart Failure (CARE-HF) trial, as mea-
sured with the EQ-5D (European Quality of Life
Instrument - 5 Dimension) and MLWHF (Minnesota
Living with Heart Failure Questionnaire), demonstrated
improved symptoms and quality of life [15]. The trial
produced 24 publications, of which 4 were PRO-specific.
The main trial publication has been cited on 4927 occa-
sions [16] and the findings have led to changes in na-
tional and international guidelines and national and
international clinical practice [17–19].
To date, however, there has been little research explor-
ing how PRO research impact is realised and measured
in practice or the barriers and facilitators to realising this
impact. Therefore, the purpose of this study was to
qualitatively explore international stakeholders’ perspec-
tives on: a) the impact of PRO trial data, b) PRO impact
metrics to measure such impact, and c) barriers and fa-
cilitators to effectively maximise the impact of PRO trial
data upon patients and society.
Methods
Design
A generic qualitative approach was chosen to explore in-
depth participants’ perspectives, specifically on the over-
all impact arising from trial PRO findings, rather than
impact associated from a particular PRO measure. Meas-
uring the impact from a single metric does not fully cap-
ture the relationships involved in a clinical trial and may
exclude some important aspects of the research pathway
[20].
This facilitated a rich description of their perspectives
while staying close to the data. In addition, this
approached was deemed suitable as no theoretical as-
sumptions were made [21, 22]. In order to obtain a
broad insight of the participants the expert purposeful
sampling method was selected [23]. One-to-one semi-
structured interviews were chosen as this qualitative data
collection method allows obtaining ‘rich’ data by build-
ing a trust relationship with the participants [24]. Finally,
the data was analysed using the reflexive thematic ana-
lysis method [25–27]. This qualitative study is reported
in accordance with the Consolidated criteria for report-
ing qualitative research (COREQ) [28].
Ethical considerations
The research followed the University Of Birmingham
Code Of Practice for Research and Data Protection and
Handling Guidelines [29]. Ethical approval was granted
by the University Research Ethics Committee in Decem-
ber 2016 (ERN_16–0806).
Sampling and recruitment
International stakeholders who spoke English and were
willing and able to give informed consent were invited
via email to take part in the qualitative interviews. Stake-
holders included: policy-makers, representatives from
regulatory agencies, funders, journal editors, academic
trialists, clinicians and industry trialists. Individuals were
eligible for interview if: a) they reported experience of
using PRO data to inform clinical practice, clinical
guidelines and health policy development; to support
drug approval, pricing and reimbursement decisions, or
to inform clinical decision-making and consent for treat-
ment; or b) they reported experience of reviewing the
PRO components of clinical trials and/or scientific pub-
lications. Initial recruitment approaches were made
through personal research networks known to the team
(MC/DK/AS) and through the identification of key au-
thors from relevant PRO literature (expert purposive
sampling [30]); further participants were identified and
recruited through snowball sampling [31].
Data collection
Semi-structured interviews were conducted by SCR be-
tween May and October 2018, either by phone or face to
face on University premises [32].
All participants gave either verbal or written informed
consent prior to each interview. An interview schedule
(Appendix 1) was used to guide the discussion. This was
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initially informed by our systematic review on PRO trial
impact [14]. It was subsequently refined after two pilot
interviews with two international stakeholders and con-
sultation with the research team (CM/DK/AS/MC). The
aim of the pilot interviews was to identify any flaws or
limitations within the interview design. As no major
changes to the interview schedule were required, these
data were included in the cohort of interviews analysed.
Table 1 provides further detail on the topics covered by
the interview schedule.
After the piloting exercise, data collection and analysis
were conducted iteratively (i.e. themes identified within
early interviews and interpreted within transcripts were
included in subsequent interviews) until analytic satur-
ation was reached. Saturation is defined as ‘data ad-
equacy’ [33], the point when data collection does not
contribute any additional information and the data col-
lected provides comprehensive information to answer
the research question [33–35]. For the purpose of this
study, saturation was reached when no new themes were
interpreted from the data [34, 35]. In this qualitative
study, saturation was determined at the stakeholder co-
hort level through review of the data and discussion
within the research team.
Data analysis
Interviews were digitally recorded and transcribed verba-
tim by a professional transcription company. Interview
data were managed using a qualitative data analysis soft-
ware package (QSR NVivo 11). Data analysis was in-
formed by the reflexive thematic analysis approach [27].
In order to support the analysis and interpretation of the
data, a multidisciplinary team including methodologists,
clinical and non-clinical experts was involved. The ana-
lysis process started with reading the transcripts several
times to increase familiarity with the data. This was
followed by deductive and then inductive coding
processes.
Deductive analysis
Initially, deductive coding was undertaken using the ‘path-
ways to research impact’ framework [20], in order to iden-
tify types of PRO trial impact and impact measurement
metrics. The framework provided a comprehensive sum-
mary of impact categories, impact subgroups and impact
metrics across five types of impact: 1) Primary research re-
lated impact; 2) Influence on decision-making; 3) Health
and health systems impact; 4) Health-related and societal
impact, and 5) Broader economic impact [20] (Appendix
Figure 1). The five impact categories of the framework
were deductively applied to the data. In instances where it
was not possible to categorise data into the existing frame-
work, they were added to a ‘miscellaneous’ coding cat-
egory. Subsequently, the data coded into each of the
impact categories was organised into subgroups.
Inductive coding
More detailed codes were described and interpreted in-
ductively within each of the five categories and the ‘mis-
cellaneous’ category. In addition, inductive coding was
also used to identify impact metrics, and barriers and fa-
cilitators to PRO trial impact, across the whole dataset.
After the coding process, and collation of codes, theme
generation continued until the definitive overarching
themes were developed [25, 27].
Following inductive coding, the transcripts were again
read several times to ensure there were no elements of
the dataset missing. During the coding stage, a random
sample of interviews (10%, n = 3) was additionally coded
by an independent researcher (CM) in order to enhance
credibility of the analysis of the data collected (analyst
triangulation) [31]. After the coding process, data were
organised and analysed following descriptive accounts by
Table 1 Summary of interview schedule
Topic area Summary of subtopics covered
a) The impact of PRO trial results Exploration of international stakeholders’ perceptions of PRO trial impact, specifically:
• Impact of PRO trial data on stakeholder’s practice
• Thoughts, opinions and experience of incorporating PRO trial data in practice
• Examples of PRO clinical trials that have led to impact
• Examples of PRO clinical trials that have not led to impact
b) Impact measurement metrics Exploration of stakeholders’ perceptions of the most effective ways to identify trials that have
led to PRO impact, specifically:
• Identify impact measurement metrics
• Identify the most effective way to measure PRO trial impact
• Thoughts and opinion of developing a framework to measure PRO trial data
c) Perceived barriers and facilitators to effectively
maximise the impact of PRO trial data upon patients
and society
Exploration of stakeholders’ perceptions of barriers and facilitators to maximise the impact of
PRO trial data, specifically:
• Thoughts, opinions and experience of facilitators to that maximise the impact of PRO trial
data
• Thoughts, opinions and experience of barriers to that maximise the impact of PRO trial data
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type of impact, impact metrics and barriers and facilita-
tors to impact [36]. Subsequently, a record was included
of the meaning of the quotes under each code. These
notes helped grouping together descriptive codes that
shared common meaning into categories in order to get
a broader sense of the data. The final stage was to group
relevant categories into themes to represent broader
concepts of the data. The themes identified were either
rearranged to create a new theme or collapsed to form a
single theme [25]. In addition, the themes were revised
to ensure they clearly and concisely described the data-
set. Quotes that highlighted the nature of each theme
vividly were chosen to demonstrate their prevalence. To
draw commonalities and differences among stake-
holders, descriptive tables were created per theme and
subsequently grouped by main topic. The tables included
quotes that helped describing the key findings from the
dataset. The respective coding, categories and themes
decisions were discussed with the research team (DK/
AS/MC) to inform the final analysis and interpretation
of the data.
Results
Of 41 stakeholders invited to participate, 24 semi-
structured interviews were conducted with a range of
international stakeholders. Reasons for declining partici-
pated included lack of availability (n = 4), preference to
maintain a neutral position regarding the topic (n = 1), be-
lief they were ineligible (n = 1). In addition, 11 people did
not respond to the invitation. Interviews lasted on average
35min (range 24 to 55min). Most of the interviews (n =
21) were conducted by phone whilst three took place face-
to-face on University premises. Interviewees self-identified
with a range of stakeholder groups including academic
and industrial trialists, journal editors, clinicians, funders
and policy-makers/regulators. Six participants identified
with more than one group. Participant summary charac-
teristics are presented in Table 2.
Interpretation of four core themes are presented in
this section: 1) types of PRO impact 2) PRO impact met-
rics and 3) barriers to PRO trial impact, and 4) facilita-
tors to PRO trial impact. To explain the dataset in a
meaningful way, an informed approach was adopted.
The dataset was presented against these four core
themes, which relate back to the five types of impact cat-
egories as appropriate throughout.
Results are presented below with quotes labelled as
shown in Table 3 followed by participant number. Devi-
ant cases were explored and presented were appropriate.
Types of PRO impact
The following section describes the different types of im-
pact identified by stakeholders in which PRO trial data
were purported to have an impact.
Primary research related impact
This is an impact associated with the generation of new
knowledge, dissemination of results, building of research
capacity, delivery of training and development of new
leadership, and academic collaborations and networks.
This impact is expected to be generated in the short-
term, one year or less [20].
Academic and industry trialists, clinicians and funders
were the main stakeholder groups that discussed the po-
tential impact of PRO trial findings on ‘research and
innovation outcomes’. They believed that publications
(including press releases and lay summaries), peer
reviewed articles and citation rates have the potential to
maximise the impact of PRO trial data outcomes by
making the PRO data available to patients, clinicians and
decision-makers. Another type of PRO impact men-
tioned was ‘dissemination and knowledge transfer’,
which participants identified as presentation of PRO trial
data in conferences by leaders or experts (including pa-
tients), mass media, and translation of PRO data to other
research areas.
“The most impactful thing is when a respected expert
gets up on the podium and says, “It’s really import-
ant that this study showed pain improvements and
we should be telling our patients that their pain gets
better.” That makes a big difference […]” CL1
See Table 1 in Appendix Table 1 for further quotes on
primary research related impact.
Influence on policy-making
This type of impact refers to the interaction between
policy-makers and academics and available knowledge
base, which may result in changes to policy. These im-
pacts are generally considered to arise in the mid-term
(1 to 3 years) [20].
Several interviewees highlighted the potential impact
of PRO trial data on ‘type and nature of policy-making’,
by influencing changes in clinical guidelines to practice
and providing information to support drug approval,
pharmaceutical labelling claims and promotional label-
ling claims.
“[…] to support a drug license, what we would hope
in the future is that patient reported outcomes are
the patient voices captured in a way, in a robust
way, and an objective way that would allow that
data to be integrated into the assessment of benefits
and risks and then concluding on whether a drug
should be given a drug license” PM-RE13
For instance, some clinicians stated that PRO trial data
had influenced their own practice by informing nuanced
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conversations with patients and supporting careful selec-
tion of treatments and giving them confidence to choose
the best healthcare treatment while considering toxicity
and side effects.
“So, for treatments that I discuss with patients,
when there are results from trials with informa-
tion about patient reported outcomes, specifically
about symptoms or physical functioning, or overall
quality of life I include those in my discussion
with patients when they’re making a decision
about a treatment.” CL1
The impact subgroup ‘type and nature of policy-
making’ was mainly discussed by academic trialists,
policy-makers and regulators. See Table 2 in Appendix
Table 2 Participants’ characteristics
Stakeholder group Country Type of institution Participant number
Academic trialists USA University 1
Australia University 2
The Netherlands University 3
Canada University 9
USA University 10
Industry trialists USA Research institute 4
USA Research institute 5
UK Pharmaceutical company 11
USA Pharmaceutical company 16
USA Global contract research organisation 17
Journal editors USA Peer-reviewed medical journal 7
UK Peer-reviewed medical journal 15
USA Peer-reviewed medical journal 24




USA Funding institute 19*
UK University 23
UK University 24*
Policy-makers and regulators USA Regulatory agency 6
UK Regulatory agency 8
Germany Reimbursement agency 12
UK Regulatory agency 13
UK Reimbursement agency 14
Funders UK Charity 18
USA Funding institute 19
UK Government 20
USA Funding institute 21
USA Funding institute 22
*Participant included in two different stakeholder groups
Table 3 Quotes labels
Stakeholder group Academic trialists Industry trialists Journal editors Clinicians Policy-makers and regulators Funders
Label AT IT JE CL PM-RE FU
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Table 1 for further quotes on influence and policy-
making impact.
Health and health systems impact
Health and health systems impact encompasses the ben-
efits of health research outputs on `quality of care and
service delivering’, ‘evidence-based practice’, ‘improved
information and health information management’, ‘cost
containment and effectiveness’, ‘resource allocation’, and
‘health workforce’. This type of impact is expected to
arise in the long-term, beyond five years [20].
Clinicians and funders were the only stakeholder
groups who highlighted the impact of PRO trial data on
‘evidence-based practice’, specifically on the subgroup
fulfilling previously unmet needs.
“Collecting PROMs on a regular basis allowed us to
demonstrate that the management of lymphoedema
within our organisation was an unmet need, and
using that data, we could then use that to influence
purchases and commissioners and make that the
backbone of a business case which allowed us to pro-
vide new services for patients with lymphoedema.”
FU18
The impact subgroup ‘quality of care and service deliv-
ery’ was only discussed among academic and industry
trialists, clinicians and funders. These stakeholder
groups emphasised the impact of PRO trial data on im-
proved health outcomes. The impact subgroup ‘cost
containment and effectiveness’ was predominant among
all the stakeholder groups but journal editors. Academic
and industry trialists and policy-makers and regulators
highlighted the impact of PRO trial data on cost
effectiveness.
“Well, I sub-divide patient reported outcomes into
disease specific PROs and generic ones. The gen-
eric ones in particular, EQ-5D. All of the trials
that we’ve seen that include the EQ-5D have used
them to calculate cost effectiveness.” PM-RE14
Academic and industry trialists, clinicians, funders
and policy-makers and regulators thought that PRO
trial data can capture improvements in health-related
quality of life that can be used in combination with
other clinical outcomes to the contribution of health
institutions cost savings. Furthermore, industry trial-
ists, clinicians and funders mentioned that the adop-
tion of a healthcare treatment that improves health-
related quality of life could have an impact on the re-
duction in the number of work loss days, which leads
to improved work productivity. The impact sub-
category ‘reduction in the number of work loss days’
is encountered within the category ‘healthy
workforce’.
“For irritable bowel syndrome […] patients had less
gas and less this and that, but also that led to im-
provement in work productivity. They went back to
work much earlier so that sort of thing certainly has
impact in certain segments of the market.” IT4
In general, clinicians and funders primarily highlighted
the impact of PRO trial data on the ‘health & health sys-
tems’ type of impact. Moreover, the impact category ‘re-
source allocation’ was not discussed by any of the
interviewees. See Table 3 in Appendix Table 1 for fur-
ther quotes on health and health systems impact.
Health-related & societal impact
Health-related and societal impact includes the impact
subgroups: ‘health literacy’, health knowledge,
attitudes and behaviours’ and ‘improved social equity,
inclusion or cohesion’. This type of impact is also ex-
pected to be generated in the long-term, beyond five
years.
Funders and a small number of clinicians highlighted
that PRO trial data can influence health literacy, by pro-
viding information on how patients are affected by a
health condition. They believed that this information
can be used to change the general perception of a dis-
ease or de-stigmatise it (e.g. cancer and mental health
conditions) and help patients ‘live better’ with that con-
dition. Industry trialists and funders considered the im-
pact of PRO trial data on patient advocacy groups,
which is encountered within the impact category health
knowledge, attitudes and behaviours. These interviewees
mentioned that patient advocacy groups can influence
drug development by communicating to health author-
ities patients’ priorities.
“I think PROs can affect the public image of the dis-
ease. I think one of the things we’re all hoping for
some day, are treatments for cancer that can help
turn what, for many people is a fear of even being
with somebody who has cancer into something more
positive, that cancer becomes something that we
treat like arthritis.” F21
Industry trialists and funders were the only stake-
holder groups that mentioned the potential impact of
PRO trial data on ‘health-related & societal impact’. Fur-
thermore, the impact category ‘improved social equity,
inclusion or cohesion’ was not discussed by the inter-
viewees. See Table 4 in Appendix Table 1 for further
quotes on health-related and societal impact.
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Broader economic impacts
This impact category refers to the generation of eco-
nomic revenue generated from the commercialisation of
health research output. This type of impact is also ex-
pected to arise in the long term. Industry trialists sug-
gested that PRO trial data can contribute to increasing
pharmaceutical companies’ sales and revenue. By using
PRO trial data to attract income from intellectual prop-
erty and increased pharmaceutical sales.
“Think in the pharmaceutical industry, because
we’re selling products, one of the main ways they
evaluate whether or not it’s a success is how much it
sells, how frequently it’s used and whether or not it
becomes part of guidelines, but that’s not the only
way to understand the value.” IT4
See Table 5 in Appendix Table 1 for further quotes on
broader economic impact.
Figure 1 provides a summary of the different types of
PRO impact interpreted within the interview dataset
drawn upon the ‘pathways to research impact’ frame-
work [20]. The impact metrics highlighted in different
colour represent new areas identified by the dataset.
Impact measurement metrics
Interviewees proposed different quantitative and qualita-
tive metrics to measure the impact of PRO trial data.
These included: the number of citations of PRO publica-
tions; journal impact factor; and how often a PRO end-
point was presented in blogs, online communities and
social media.
“How many times the article on the PRO’s has been
cited. That’s one measure. The standard metrics that
the journals and articles have regarding impact.”
IT16
Additional impact metrics proposed included: number of
clinical trials conducted which included PROs as an endpoint
and number of labelling claims. Evaluation of health technol-
ogy assessment documentation to determine whether PRO
Fig. 1 Impact measurement metrics
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data inform drug approval. Surveys and interviews among
healthcare practitioners and patients to determine whether
PRO data are incorporated into clinical decision-making or
used to inform patient shared decision-making.
“I think there are experimental methods that could
be applied, so sampling, […] there’s quantitative sur-
vey methods that could be used, but also qualitative
methods to be sure to be capturing what its impact
is, for instance, how information from a PRO af-
fected thinking and behaviour on the part of the end
user. By end user I mean an individual with a con-
dition or a clinician and even to the level of the
health system.” FU21
In contrast, several stakeholders highlighted that meas-
uring PRO trial data through metrics is a challenging
task and it might not accurately represent the real im-
pact of PRO trial data.
Barriers to PRO impact
Interviewees highlighted a range of perceived barriers
that they felt may impair the realisation of impact arising
from PRO trial findings, including: 1) poor quality trial
design, 2) suboptimal conduct and analysis, 3) poor
reporting quality, and 4) dissemination and uptake of
PRO results.
Poor quality trial design
Poor quality trial design refers to the lack of PRO-
specific methodological rigor during the design stage of
the clinical trial, which limits the realisation of PRO trial
impact in the subsequent stages of the clinical trial. All
stakeholder groups, with the exception of industry trial-
ists and funders, mentioned poor quality design as one
of the barriers to PRO impact. Interviewees highlighted
PRO trial barriers such as lack of detailed PRO protocol
and lack of adherence to it.
“[PROs are] either exploratory endpoints that are ei-
ther added in inappropriately, the timings are incor-
rect, the instrument might not be correct for the
particular patient population, the analysis hasn’t
been thought through, there’s no hypothesis or objec-
tives listed in the study protocol.” PM-RE13
Further barriers identified were the inclusion of PROs
in the clinical trial as secondary outcome, lack of PRO
trial information from phase I and II limiting the design
of the PRO component in phase III and; late or not in-
corporation of PRO experts in the development of the
clinical trial protocol.
"[…] we would get sent the protocol right at the end,
right before the trial was going to be sent to ethics or
sometimes even after they had received ethical ap-
proval. We would make suggestions to improve the
protocol with respect to PRO’s and then some of the
investigators would be reluctant to make those
changes because it meant they would have to do an
extensive protocol amendment" AT2
See Table 1 in Appendix Table 2 for further quotes on
poor quality trial design.
Suboptimal conduct and analysis
The way the trial was conducted and the type of analysis
that is implemented were mentioned as barriers to maxi-
mise the impact of PRO trial data. Suboptimal conduct
and analysis was a predominant theme among all the
stakeholders; however, it was discussed to a lesser degree
by journal editors and clinicians. This theme included
barriers related to high rates of missing data, difficulty
collecting PRO data among global trials, patient and staff
burden and lack of training for clinicians to optimally
conduct a PRO clinical trial and analyse PRO trial data
and; lack of expert reviewers to assess PRO trial results.
"Medical journals often lack sufficient experts who
can review PRO results because the researchers and
clinicians who are journal reviewers are not
knowledgeable about PRO[s]." IT11
An additional barrier identified surrounded a per-
ceived lack of understanding and interpretation of PRO
data by clinicians, patients and patient advocates.
“PRO experts, sometimes assume that the clinicians
will understand tables and figures and the interpret-
ation of the clinical trial and I think we know from
experience that clinicians don’t always get the mes-
sage.” IT17
See Table 2 in Appendix Table 2 for further quotes on
suboptimal conduct and analysis.
Poor reporting quality
This theme was primarily highlighted by academic trial-
ists. Barriers emphasised by interviewees included: lack
of discussion of PRO outcomes; inclusion or detailed in-
formation within the main clinical trial publication; PRO
data explanation in view of other clinical endpoints and;
publication of PRO trial data many years after publishing
the main trial manuscript or its lack of publication.
“I came across a few trials where the PRO results
hadn’t been published […] I saw that certain trials
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had PRO of secondary endpoint but then when I
found the publication that related to it, that was just
completely missing and sometimes they would say
that the PRO results would be published later but it
had been several years down the track.” AT2
Further barriers to PRO impact interpreted included
publication of clinical trials manuscripts including PRO
data in a technically correct language, but difficult to
understand for patients, advocacy groups and patients
and; restricted access to PRO publications (paywall re-
strictions). See Table 3 in Appendix Table 2 for further
quotes on poor reporting quality.
Dissemination and uptake of PRO results
This included PRO-specific issues faced upstream that
limited the propagation and adoption of the findings
into clinical practice. This theme was common among
journal editors, clinicians and policy-makers and regula-
tors, whereas academic trialists commented on this
theme to a lesser extent.
Barriers encompassed lack of awareness of PRO data
importance between clinicians, researchers, journal edi-
tors and sponsors and; prioritisation of clinical outcomes
over PRO trial data by researchers and funders.
“The main reason is that the high impact journals
want survival data and if they’ve got a survival ad-
vantage they don’t bother with the quality of life
data. […] There’s a study of a drug which has a two-
month survival advantage, worse toxicity, quality of
life data collected but not published. It’s outrageous.”
FU19
Additional barriers discussed were lack of engagement
between academic researchers and research companies
with patients to understand patient priorities, collabor-
ation between PRO researchers within same health re-
search areas and law or regulation in the UK to enforce
the collection of HRQL in clinical trials.
"So we are law enforcers if you like. Now, that
doesn’t really incorporate PRO’s, there is no specific
law if you like, that they’re going to break if they
don’t include a PRO or include it in the wrong
context or what have you. So it’s almost, I suppose,
supplementary information. It’s not regulated in any
way in terms of black and white text." PM-RE8
Other barriers that reportedly might hinder the maxi-
misation of PRO trial data were the limitation of PROs
not automatically becoming health utilities, the different
perspective surrounding the inclusion of PROs in clinical
trials between the EMA (European Medicines Agency)
and FDA (Food and Drug Administration) and the diffi-
culty getting funding for PRO research.
“One of the major funders of research in this country
is very unlikely to fund research that has a PROM
as a primary outcome. They’ve made that a strategic
intent, so the playing field is already biased against
PROM’s based research.” FU18.
See Table 4 in Appendix Table 2 for further quotes on
dissemination and uptake of PRO results.
Facilitators to PRO impact
Interviewees highlighted a range of perceived facilitators
that they felt may enhance the realisation of PRO trial
findings including: 1) improved PRO trial design, 2) op-
timal conduct and analysis, 3) improved reporting and
4) dissemination and uptake of PRO results.
Improved PRO trial design
This theme was primarily discussed by policy-makers
and regulators. It was not discussed among journal edi-
tors and clinicians. Improved PRO trial design facilita-
tors discussed by interviewees included: the production
of a clear and detailed PRO protocol; endorsement of
the PRO data as a key endpoint in clinical trials; and
early incorporation of a PRO expert in the trial team.
"There should be a PRO expert on the clinical trial
team and at the earliest possibility; if you start
thinking about your PROs at the reporting stage it is
far too late. You need to be thinking much earlier
on." AT3
Participants also discussed adherence to PRO guide-
lines, inclusion of patients and clinicians in the trial de-
sign stage, regular meetings with regulatory agencies
during the planning period and the end of the trial and;
the development of PRO measures while considering
health utilities for HTA use.
"The patient reported outcomes world could think of
utilities at the same time as developing their PRO’s.
So any patient reported outcome that has got a util-
ity mapping attached to it is very useful." PM-RE14
See Table 1 in Appendix Table 3 for further quotes on
improved PRO trial design.
Optimal conduct and analysis
Facilitators to achieve optimal conduct and analysis were
highlighted by policy-makers and industry trialists,
whereas journal editors and clinicians did not contribute
to this theme. Facilitators discussed were high
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completion rates of PRO trial, training sites on the ad-
ministration, make PRO data more readily understand-
able and; explanation of PROs and standardisation of
PRO tools among therapeutic areas to improve analysis.
"Having standardised tools across trials helps us
understand the trial results and be able to compare
things more easily. [...] Certainly in the US with
qualification process for PROs, there’s a hope that
each of us will not go out and create one off our own
tool, instead have some standardisation." IT5
See Table 2 in Appendix Table 3 for further quotes on
optimal conduct and analysis.
Improved reporting
Improved reporting was predominant among aca-
demic trialists and journal editors; however, this
theme was not discussed by industry trialists, policy-
makers, and regulators. Facilitators encompassed in
this theme were open access publications and PRO
trial data reported in the main publication and in a
high impact journal.
"The studies which have been impactful have been
ones where the quality of life data and the survival
data has been published together in a high impact
journal" FU19
Further facilitators comprised simple English summary
of the trial results for use of patients, availability of more
journals to publish PRO trial data and make PRO instru-
ments available through publications. See Table 3 in
Appendix Table 3 for further quotes on improved
reporting.
Dissemination and uptake of PRO results
Finally, dissemination and uptake of PRO results was
emphasised by all the stakeholders but to a lesser ex-
tent by policy-makers and regulators. This theme
highlighted facilitators such as adequate funding and
the important of funders clearly stating their position
around PROs and their expectations of the funded
PRO research.
“I think funders have a role because they can stipu-
late, for example, that the work they fund must have
some sort of an implementation plan so that work
isn’t just completed and then perhaps published in a
journal and then never heard from again. Having
emphasis on ensuring that there is some pull through
into use and impact as a direct requirement of fund-
ing would go a long way as well to help the prob-
lems.” FU21
In addition, it was suggested that funders should require
an implementation plan in terms of usage and impact of
the PRO clinical trial as a direct requirement of funding.
Facilitators suggested that might enable the dissemin-
ation and uptake of PRO results included: provide PRO
training courses for clinicians and drug developers and
communicate PRO research widely through the involve-
ment of key opinion leaders, specifically at healthcare
conferences.
"To allow organisations like the NCRI, ASCO,
ESTRO, the organisations that host large healthcare
provider conferences to make PROM’s based research
a future of their sessions and their main talks and
also to improve quality of science communications so
that we have skilled science communicators dissem-
inating these results." FU18
Further facilitators highlighted included empowerment
of patients through their involvement in discussions and
dissemination of PRO trial results and; endorsement of
PRO trial studies by key societies to disseminate results
and influence healthcare policy. See Table 4 in Appendix
Table 3 for further quotes on dissemination and uptake
of PRO results.
Discussion
For the first time, this study provides international
stakeholder perspectives on the types of impact asso-
ciated with PRO trial results, impact measurement
metrics, and barriers and facilitators to effectively
maximise the impact of PRO trial data upon patients
and society.
Stakeholders identified a number of ways in which
PRO data from clinical trials can potentially inform/in-
fluence primary research, policy-making, health and
health systems, health-related and societal impact and
broader economic impacts. Although every interviewee
was asked similar questions, not all of them discussed
each type of impact. It was interpreted from the data
that stakeholders appeared to focus on the impact cat-
egories that were most relevant to them and did not
focus on broader aspects of PRO impact, even when
prompted. The dataset provided rich narratives when
the interviewee had experience of a particular type of
PRO impact. For instance, academics primarily focused
on ‘primary research related impact’. Arguably this
stakeholder group might be more focused on producing
research outcomes and their dissemination, rather than
the broader benefits these outcomes may have on pa-
tients and society. Nonetheless, PRO stakeholders agreed
on the benefit of including PROs in clinical trials and
did consider a range of impacts.
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The majority of the stakeholders suggested that meas-
uring the impact of PRO trial research can benefit aca-
demic researchers, trialists, policy-makers, regulatory
authorities, funding bodies, pharmaceutical companies,
payers and patients. Measuring the impact of PRO trial
findings may help stakeholders understand the import-
ance and value of PRO trial data, broaden their perspec-
tives regarding PRO applicability, and identify the
different benefits to society through improved health
outcomes and use of resources [37]. For instance, these
data would provide a knowledge base to policy-makers,
regulators and funders to justify drug approval and in-
form funding allocation decisions through demonstrat-
ing the potential benefits on patients and society [20,
38]. Moreover, journal editors and academics might be
more likely to acknowledge the importance of PRO data
and ensure timely, transparent publication of PRO trial
data in high impact journals. Considering the impact of
PRO trial impact, it has the potential to influence the
study design and determine the possible benefits of con-
ducting a particular study. Table 4 provides an example
of PRO clinical trial that led to impact.
Furthermore, stakeholders proposed several qualita-
tive and quantitative metrics to measure the impact
of PRO research. Quantitative metrics included num-
ber of publications, citations including PROs as an
endpoint and number of regulatory approvals includ-
ing PROs and; surveys among stakeholders and
patients to determine how PRO data are being used.
Qualitative metrics comprised interviews among
people involved in the drug approval process to deter-
mine whether PRO trial data inform drug approval
appraisal. Certain metrics may be more important to
particular stakeholders but should be considered for
academic and industry trials collecting PROs.
However, most interviewees highlighted that measuring
the impact of PRO trial research is a challenging task as it
cannot be captured systematically. Single cross-sectional
metrics tend not to represent the overall impact PRO trial
data can have, since impact arises at different points in
time [20, 45]. In addition, impact is defined by each stake-
holder group in a different way. For instance, academics
considered impact in terms of number of publications and
journal impact factor; policy-makers and regulators in
terms of changes to healthcare policy and number of drug
approvals. The most appropriate way to measure PRO
trial data will depend on each stakeholders’ needs. The
‘pathways to research impact framework’ [20] proposes
different quantitative and narrative metrics to measure
such impact; however, research teams may wish to use a
multidimensional approach that may present a more com-
prehensive method of measuring impact. Nonetheless, fur-
ther work should be done to determine the effectiveness
of the impact metrics identified.
Several methodological PRO-specific trial barriers were
identified including poor quality trial design, suboptimal
trial conduct and analysis and poor reporting quality.
Interestingly, funders did not raise poor quality trial de-
sign as an issue in their interviews but arguably should be
concerned with the quality of the data collected, as it is
considered a crucial barrier to the realisation of PRO trial
impact downstream. It is important that trialists consider
the rationale for PRO assessment at the start of the study
and select appropriate measures to help realise the impact
that they wish to achieve. For example, use of health utility
measures to inform CE analyses and disease specific mea-
sures to inform clinical practice.
Facilitators to maximise the impact of PRO trial data
were discussed among stakeholders. Main facilitators
highlighted were: mandatory inclusion of PRO data in
funded trials and publications where appropriate; and
the requirement to provide an implementation plan de-
tailing the proposed use and impact of PRO clinical trial
data as a direct requirement of funding. Additional facil-
itators included the importance of communicating PRO
research widely, specifically at healthcare conferences
Table 4 Impact of PRO trial data: a practical example
Tocilizumab, a new treatment for rheumatoid arthritis (RA) in adults and
juvenile idiopathic arthritis (JIA) in children showed significant
improvements.
Patients improved 30% or more on at least three of the six variables in
the American College of Rheumatology (ACR) core set for JIA, with no
more than one variable worsening by more than 30%. Furthermore,
patients showed improved symptoms such as absence of fever and
rash, as measured with the Disability Index of the Childhood Health
Assessment Questionnaire (CHAQ-DI) and; improved laboratory
abnormalities (anemia, thrombocytosis, and hyperferritinemia) – primary
outcome [39].
Drug approval: Tocilizumab was approved in 2009 by the EMA
(European Medicines Agency) [40] and by the FDA in January 2010 [41]
for use in RA based on clinical and PRO findings.
Health improvements: Tocilizumab has been supported for
prescription by NICE in the UK for patients with severe RA. There is
evidence that tocilizumab halts joint damage, improves function and
increases quality of life [39]. Significantly more patients treated with
tocilizumab showed improvements of ≥0.3 units in the HAQ-DI score
compared to patients treated with placebo [39].
Informed cost-effectiveness: The National Institute for Health and
Clinical Excellence (NICE) recommended the use of tocilizumab for
systemic onset JIA, the most severe form of JIA, in 2011. The
manufacturer’s submission mapped the CHAQ-DI scores to utilities,
using a mapping formula derived in adults with rheumatoid arthritis that
mapped Health Assessment Questionnaire [HAQ] results onto EQ-5D
utilities to determine the effectiveness of the intervention [42].
Reduction in the number of work loss days: according to a case
study presented by the National Rheumatoid Arthritis Society, patients
under tocilizumab are able to return to work as the drug halts joint
damage and improves function [43].
Income from the intellectual property: Roche, manufacturer of the
drug, reported 496m CHF (£335m) in sales of the drug in just the first
half of 2013 (up 33% on the previous year, due to increasing demand)
[44].
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hosted by organisations such as NCRI (The National Re-
search Cancer Institute), ASCO (American Society of
Clinical Oncology), and ESTRO (European Society for
Radiotherapy & Oncology). It also felt important to em-
power patients by including them in the dissemination
of PRO results at these healthcare conferences. Further-
more, the development of a UK law to enforce the col-
lection of PRO data among clinical trials is considered
as essential.
Currently, PRO stakeholders are making concerted ef-
forts to improve the collection of PRO data in oncology
and cardiology areas. For instance, the European Society
of Cardiology (ESC) has led initiatives to increase the
prominence of PROs in cardiovascular research, which
can be translated in benefits for patients, clinicians,
payers and policy-makers [46]. The Food and Drug Ad-
ministration (FDA) is currently developing patient-
focused drug development (PFDD) guidance to address
how stakeholders can collect and include PROs from pa-
tients and caregivers in the development and regulation
of medical products [47]. In 2016, the EMA published
Appendix 2 to the guideline on the evaluation of anti-
cancer medicinal products in man. This provides a gen-
eral overview of the use of PRO endpoints in oncology
studies and the value of this information from the regu-
latory perspective [48].
Additional initiatives include PROTEUS Consortium
(Patient-Reported Outcomes Tools: Engaging Users &
Stakeholders) [49], which aims to promote the uptake
and use of tools to support high quality PRO trial data
including tools such as: SPIRIT (Standard Protocol
Items: Recommendations for Interventional Trials)
PRO-Extension [12]; ISOQOL (International Society for
Quality of Life Research) Minimum Standards for PRO
Measures in patient-centered outcomes and comparative
effectiveness research [50]; SISAQOL (Setting Inter-
national Standards in Analysing Patient-Reported Out-
comes and Quality of Life Endpoints Data) [51];
CONSORT (Consolidated Standards of Reporting Trials)
PRO-Extension [52] Stakeholder-Driven, Evidence-Based
Standards for Presenting PROs in Clinical Practice [53];
and Clinician’s Checklist for Reading and Using an Art-
icle About PROs However, greater work needs to be
done to capture PRO data in a rigorous efficient way
across disciplines. Furthermore, key societies like Mac-
millan Cancer Support, ASCO and the NCRI are work-
ing on the endorsement of the dissemination of PRO
trial studies, which might help to have a wider reach for
spreading PRO trial results and consequently a further
impact [54, 55].
Strengths and limitations
One of the key strengths of this study was the inclusion
of 24 internationally recognised PRO experts. We
consider the interviews captured all the core concepts
around the impact of PRO trial data, which are pre-
sented above in four different themes. SCR, the inter-
viewer, did not have a relationship with the participants;
however, the wider team (MC/DK/AS) had previous col-
laborative links with some of the participants. To reduce
the potential misinterpretation of data, the multidiscip-
linary team provided support for the analysis and inter-
pretation of the data.
A further limitation was that since participants were
recruited from a pool of stakeholders known to the re-
search team, this might have limited the range and ex-
perience of stakeholders being interviewed. Seventeen
invitees declined to participate in the research, which
could have led to the exclusion of relevant individuals
with a different perspective. Whilst we did not ask for a
reason why they declined participation, it is possible that
they may have been less aware of the potential benefits
of PRO trial data and/or the importance of sharing their
views irrespective if they did or did not see the benefits
of these data.. Nonetheless, we attempted to interview as
wide a range of stakeholders as possible using purposive
and snowball recruitment methods.
Saturation within each stakeholder group would have
been ideal but this was not possible. This would have
allowed stronger conclusions to be drawn around the
similarities and differences between each stakeholder
group. Where there was appropriate evidence, similar-
ities and differences were highlighted. Qualitative ex-
perts were involved to ensure congruence and structure
at each stage of the research.
Finally, the findings drawn from this study may be
transferable to other researchers working on PRO clin-
ical trials, who have knowledge of the area. This reflects
the need to have a PRO expert as part of the clinical trial
team and; make the research accessible and applicable
across a broad spectrum of international stakeholders.
Conclusion
In this study, we have presented the perspectives of
international PRO stakeholders on the impact of PRO
trial data, impact measurement metrics, and barriers and
facilitators to effectively maximise the impact of PRO
trial data upon patients and society. Interviewees
highlighted a range of potential impacts associated with
PRO trial findings, most notably the influence on policy-
making. However, there is a need to find more compre-
hensive ways of measuring PRO impact. There a number
of barriers that needs to be overcome to facilitate PRO
impact. Stakeholders need to come together to address
these challenges in order to optimise the uptake of PRO
trial findings in practice and maximise the benefit to pa-
tients and society.
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